Zacks Research Has Pessimistic Outlook of IRWD Q3 Earnings

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) – Zacks Research decreased their Q3 2026 earnings per share estimates for Ironwood Pharmaceuticals in a report released on Wednesday, March 26th. Zacks Research analyst R. Department now expects that the biotechnology company will post earnings of $0.07 per share for the quarter, down from their prior estimate of $0.08. The consensus estimate for Ironwood Pharmaceuticals’ current full-year earnings is $0.10 per share. Zacks Research also issued estimates for Ironwood Pharmaceuticals’ Q4 2026 earnings at $0.06 EPS and FY2026 earnings at $0.23 EPS.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its earnings results on Thursday, February 27th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.08). The firm had revenue of $90.55 million during the quarter, compared to analysts’ expectations of $93.85 million. Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%.

Other analysts also recently issued reports about the company. Craig Hallum cut their target price on Ironwood Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Wednesday, January 22nd. StockNews.com upgraded shares of Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday. Finally, JMP Securities decreased their price objective on shares of Ironwood Pharmaceuticals from $23.00 to $14.00 and set a “market outperform” rating for the company in a report on Thursday, January 30th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $8.60.

Ironwood Pharmaceuticals Stock Down 3.4 %

Shares of IRWD opened at $1.41 on Friday. Ironwood Pharmaceuticals has a twelve month low of $1.34 and a twelve month high of $8.64. The company has a market capitalization of $225.64 million, a P/E ratio of -47.00 and a beta of 0.37. The firm has a 50 day moving average of $2.04 and a 200 day moving average of $3.39.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. boosted its position in shares of Ironwood Pharmaceuticals by 10.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 33,932 shares of the biotechnology company’s stock worth $150,000 after acquiring an additional 3,209 shares during the last quarter. Quantinno Capital Management LP lifted its stake in Ironwood Pharmaceuticals by 40.0% in the 3rd quarter. Quantinno Capital Management LP now owns 19,191 shares of the biotechnology company’s stock worth $79,000 after purchasing an additional 5,482 shares in the last quarter. Swiss National Bank boosted its holdings in shares of Ironwood Pharmaceuticals by 2.2% during the 4th quarter. Swiss National Bank now owns 282,700 shares of the biotechnology company’s stock valued at $1,252,000 after purchasing an additional 6,000 shares during the last quarter. Teacher Retirement System of Texas grew its position in shares of Ironwood Pharmaceuticals by 19.6% during the fourth quarter. Teacher Retirement System of Texas now owns 42,893 shares of the biotechnology company’s stock valued at $190,000 after purchasing an additional 7,020 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Ironwood Pharmaceuticals in the fourth quarter worth about $36,000.

Insider Activity at Ironwood Pharmaceuticals

In related news, CMO Michael Shetzline sold 41,269 shares of the stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $1.76, for a total transaction of $72,633.44. Following the completion of the sale, the chief marketing officer now owns 554,007 shares in the company, valued at approximately $975,052.32. This trade represents a 6.93 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Thomas A. Mccourt sold 139,064 shares of the business’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $1.76, for a total value of $244,752.64. Following the completion of the transaction, the chief executive officer now directly owns 1,160,634 shares in the company, valued at approximately $2,042,715.84. This represents a 10.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 192,381 shares of company stock worth $338,591. 12.90% of the stock is owned by company insiders.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.